family with sequence similarity 224 member BGenealiases: LINC00230B · NCRNA00230B
Q-omics provides the consensus-scored FAM224B profile across patient tissues and cancer cell-line models. FAM224B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM224B is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, FAM224B RNA expression shows 4,234 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, KIRC, and HNSC as cancer lineages where FAM224B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM224B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM224B survival associations across molecular data types. FAM224B RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM224B RNA expression–survival associations across cancer types. High FAM224B expression shows unfavorable associations in UCEC, KIRP, UVM, COAD, KIRC and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM224B RNA expression.
This table summarizes FAM224B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM224B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM224B shows lower tumor expression in KIRC and KIRP and higher tumor expression in BRCA and THCA. The KIRC box plot shows higher FAM224B RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p < 0.001).
This table shows molecular features associated with FAM224B in patient tissues and cancer cell lines. In patient samples, FAM224B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
